Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma

Refractory Glioblastoma Clinical Trial

Official title: A Pilot Study of Elemene Injectable Emulsion in Treating Patients With Refractory Glioblastoma

Status Not yet recruiting

Clinical Trial Summary

This is a pilot phase I study to evaluate the safety and efficacy on elemene injectable emulsion in treating patients with glioblastoma. Elemene, isolated from the Chinese medicinal herb Curcuma wenyujin, was shown to exhibit antitumor activity in human and murine tumor cells in vitro and in vivo.Elemene injectable emulsion against malignant tumors was low. Therefore, the effect of Elemene injectable emulsion being used in clinical settings needs to be confirmed by further RCTs.

Clinical Trial Description

Background - Elemene, isolated from the Chinese medicinal herb Curcuma wenyujin, was shown to exhibit antitumor activity in human and murine tumor cells in vitro and in vivo - The study shows that the methodological quality of RCTs of Elemene injectable emulsion against malignant tumors was low. Therefore, the effect of Elemene injectable emulsion being used in clinical settings needs to be confirmed by further RCTs Objectives - To evaluate the safety of Elemene injectable emulsion to treat Refractory Glioblastoma with TMZ - To evaluate the efficacy of Elemene injectable emulsion to treat Refractory Glioblastoma with TMZ Design This clinical trail is a randomized controlled trial.In control group,patients will receive TMZ-chemotherapy.In experimental group,patients will receive elemene injectable emulsion and TMZ-chemotherapy at the same time. ;

Related Conditions & MeSH terms

• Glioblastoma
• Refractory Glioblastoma

• NCT number: NCT04674527
• Study type: Interventional
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: Jianmin Zhang, MD
• Phone: 8613805722695
• Email: 2307010@zju.edu.cn
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 1, 2021
• Completion date: June 1, 2023